ArticleNature communications2025

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Matthew Stephen Block et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.